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The antigenically variant Chlamydia trachomatis major outer membrane protein (MOMP) is a target of
antibody-mediated neutralization in vitro, and it is an important protein for designing a subunit vaccine.
Knowledge of MOMP T-cell determinants will be essential to elicit rapid and strong immune responses
following an encounter with infectious organisms. C. trachomatis-specific T-cell lines were derived from
MOMP-immunized BALB/c mice and selected with intact organisms. We used these short-term T-cell lines to
identify determinants ofMOMP that could be recognized byT cells following processing of the intact organism.
T-cell line proliferation in response to overlapping MOMP peptides showed that only a peptide encompassing
the third variable segment (VS3) elicited a strong proliferative response. We further mapped determinants
within the VS3 peptide and found that a sequence-conserved portion of the VS3 peptide elicited T-cell
proliferation of T-celi lines from BALB/c mice. Thus, unlike the response to several MOMP peptides with
unselected T cells, development of short-term T-cell lines with intact organisms restricted the repertoire of
antigens capable of being recognized by MOMP-specific T cells.
Chlamydia trachomatis is an obligate intracellular bacte-
rium that infects the mucosal epithelium of the eye and the
genital tract. C. trachomatis ocular infections can lead to
trachoma, the single most important cause of preventable
blindness worldwide (5). Attempts to control trachoma in
developing countries by the use of widespread antibiotic
therapy have not succeeded (4). In the industrialized world,
chlamydial infections of the urogenital tract are a leading
cause of sexually transmitted disease. Because these infec-
tions are frequently asymptomatic, treatment may not be
sought until serious sequelae have developed. The conse-
quences are particularly severe in women, since genital-tract
infection can often lead to pelvic inflammatory disease,
ectopic pregnancy, or tubal infertility (10).
An effective vaccine would significantly enhance efforts to
control both trachoma and the highly prevalent sexually
transmitted infections. Because of the immunopathological
nature of chlamydial disease, attempts at vaccination with
the intact bacterium have led to more severe disease in some
individuals, with only limited protection from reinfection in
others (7). In human trials, protective immunity is serovari-
ant specific, and numerous animal models have shown that
this protective response is T-cell dependent (11). Since there
are over 15 serological variants of C. trachomatis and
because there exists the potential for eliciting immunopatho-
logical responses, a subunit approach to vaccine develop-
ment may be the most useful.
The serovar-specific protective antibody responses are
directed at the surface-exposed, major outer membrane
protein (MOMP) ofC trachomatis (3), and MOMP has thus
been the primary focus of vaccine-based research. Sequence
analysis of MOMP has revealed that amino acid sequence
variation between isolates accounts for the antigenic diver-
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sity of this pathogen (13). There are four sequence-variable
segments (VS) of the molecule, flanked by five sequence-
conserved segments. Monoclonal antibody mapping has
determined that complement-independent, neutralizing,
type-specific responses are directed at the first and second
VS (2, 14, 16).
We recently used recombinant MOMP fusion peptides in
an in vivo functional assay to define regions of the molecule
capable of eliciting T-cell help for the production of protec-
tive antibody (1) and found that with BALB/c mice, a single
region of MOMP encompassing the third VS (VS3) is par-
ticularly effective in these assays. In the present study, we
produced short-term T-cell lines to evaluate MOMP peptides
in an in vitro proliferation format. Of the nine recombinant
peptides delineating the MOMP protein, only the peptide
encompassing VS3 elicited proliferation with chlamydia-
specific BALB/c T-cell lines. Further, we identified that a
sequence-conserved region of the peptide was stimulatory in
these assays. These results demonstrate a marked correla-
tion between in vivo analysis of T-cell help and evaluation by
short-term T-cell line proliferation in vitro.
MATERUILS AND METHODS
Growth and purification ofC. trachomatis. Ocular strains of
C. trachomatis, B/TW-5/OT and C/TW-3/OT, have been
described previously (8). Infectious organisms, elementary
bodies (EBs), were grown in McCoy cells, harvested at 72 h,
and purified on Renografin gradients as described previously
(8). EB preparations were quantitated by Lowry protein
determination.
Amplification and cloning of MOMP fragments. The clon-
ing of nine overlapping MOMP gene fragments (CS1, VS1,
CS2, VS2, CS3, VS3, CS4, VS4, and CS5 [Fig. 1]) into
pGEX has been described previously (1). Smaller VS3
fragments (GG, KE, and AE) were amplified and cloned as
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Cs1 CS2 CS3 CS4 CS5
vsi V82 VS3 VS4
Glyl91- Gk1251 (GE)
wrovarB GASFOYAOSKPKVEELNVLCNAAEFTI NKPKGYVGKELPLDLTAGTDAATGTKDASIDYHE
GIyl91- Gh 251 (GE)





Lys 226- GWu251 (KE)
swrovarB KE L PL DLT AGT DAATGTK DAS IDYHE
Ala 226- MM5 AE)rovarC AEFPLN ITAGTEAATGTKDASIDYHE
FIG. 1. MOMP peptides expressed as fusion peptides with GST. The nine overlapping peptides derived from the serovar B MOMP
sequence are shown and have been described in detail previously (1). The sequence of the VS3 peptide is shown, as well as those of the
smaller peptides used for mapping of T-cell recognition sites within VS3. Stars indicate amino acid differences between the serovar B and
serovar C sequences. The identities of VS3 peptides used in subsequent figures are in parentheses.
described for the nine MOMP fragments. The following
oligonucleotides were used for polymerase chain reaction
amplification of peptides GG, KE, and AE: for Gly-191-Gly-
225 (GG), 5'-GCA-GGA-TCC-CGA-GCT-TCT-TTC-CAA-
TAT-GC-3' and 5'-AAT-GAA-TTC-CCT-ACA-TA(C/T)-
CCT- TTA- GG(C/T)-T7-3'; for Lys-226-Glu-251 (KE),
5'-TAT-GGA-TCC-AAG-GAA-TTG-CCT-CTT-CTIT-GAT-
CTT-3' and 5'-TTG-GAA-TTC-ATG-GTA-(A/G)TC-AAT-
AGA-GGC-3'; and for Ala-226-Glu-251 (AE), 5'-TAT-GGA-
TCC-GCG-GAA-TTT-CCA-CTT-AAT-ATT-3' and 5'-TTG-
GAA-TTC-ATG-GTA-(A/G)TC-AAT-AGA-GGC-3'. Fusion
peptides GG (from serovars B and C), KE (from serovar B),
and AE (from serovar C) (Fig. 1) and the glutathione-S-
transferase (GST) control were prepared and purified as
previously described for nine MOMP fusion peptides (1, 12).
MOMP purification. Purified serovar B or C EBs were
boiled in sodium dodecyl sulfate (SDS) sample buffer con-
taining 5% ,3-mercaptoethanol, and proteins were separated
by SDS-polyacrylamide gel electrophoresis (PAGE). MOMP
was localized by Coomassie brilliant blue staining of a
vertical gel strip. The MOMP band was excised from the
unstained gel, ground into a fine particulate, and placed in
phosphate-buffered saline overnight. The MOMP eluted in
this manner was analyzed for purity by SDS-PAGE and
quantitated by Lowry protein determination.
Preparation of short-term MOMP-specific T-celi lines. Fe-
male BALB/c/by mice aged 6 to 8 weeks were obtained from
Jackson Laboratories (Bar Harbor, Maine). The mice were
immunized by subcutaneous injection with 10 ,ug of MOMP
from either serovar B or serovar C emulsified in complete
Freund's adjuvant. Popliteal lymph nodes were removed
from three mice 10 days after immunization, and single-cell
suspensions were prepared by filtering through a fine-mesh
metal screen. Lymph node cells (4 x 106/ml) were cultured
in 75-cm2 flasks in RPMI 1640 with 1 mM 2-ME, 1 ,uM
glutamine, 2 puM sodium pyruvate, 100 U of penicillin per ml,
100 p,g of streptomycin per ml, and 0.5% mouse serum at
37°C in an atmosphere of 5% CO2. Cells derived from mice
immunized with serovar B MOMP were cultured with 5 pug
of serovar B EBs or 2 ,ug of GST-VS3-B (serovar B se-
quence) per ml. Cells derived from mice immunized with
serovar C MOMP were cultured with 5 ,ug of serovar C EBs
or 2 p,g of GST-VS3-C (serovar C sequence) per ml. After 4
days of stimulation culture with specific antigen, T cells
(105/ml) were cultured for 7 days with 106 accessory cells per
ml in the absence of antigen and with 7% rat concanavalin
A-stimulated medium and 10% fetal bovine serum instead of
mouse serum (rest culture). Viable cells were isolated for
assay by Ficoll separation. Fluorescence-activated cell
sorter analysis demonstrated that T-cell lines prepared in
this manner were >90% CD4+. Accessory cells were pre-
pared by irradiation (3,000 rads with 137Cs) of single-cell
suspensions of syngeneic spleen cells.
T-cell proliferation assay. Ficoll-purified T cells obtained
following 11 days of culture, irradiated accessory cells, and
antigens were diluted in RPMI 1640 with 1 ,M glutamine, 2
,uM sodium pyruvate, 100 U of penicillin and 100 p.g of
streptomycin per ml, and 10% fetal bovine serum. A 100-pl
volume of 10 T cells and 107 accessory cells per ml were
placed in 96-well U-bottom plates. A 100-pl volume of
medium with various concentrations of either fusion protein
or purified EBs was added to the wells. Antigens were tested
in triplicate wells. After 4 days of incubation, 0.5 pCi of
tritiated thymidine ([3H]TdR) was added to each well and
incubated overnight. The cells were harvested onto filters
with a cell harvester, and [3H]TdR incorporation was mea-
sured in a liquid scintillation counter. The results are ex-
pressed as stimulation indices (SI), where SI = counts per
minute in test well/counts per minute in medium control
well.
RESULTS
In vitro mapping of MOMP T-cell recognition sites.
BALB/c mice were immunized with purified MOMP, and
short-term T-cell lines were produced by 4 days of stimula-
tion with intact organism followed by 7 days of culture in the
absence of antigen. These cells, now predominantly CD4+,
were used in a T-cell proliferation assay to measure the
stimulatory capacity of nine MOMP fusion peptides (Fig. 1).
In this assay format, only the peptide encompassing VS3
was stimulatory (Fig. 2). In contrast, we had previously
tested the ability of these nine MOMP fusion peptides to
elicit proliferation of T cells derived from the spleens of
chlamydia-infected mice. In these primary-culture assays,
several of the MOMP peptides generated proliferative re-
sponses (1). Su et al. (15) also observed several MOMP
peptides that were capable of eliciting T-cell proliferation of
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0I1.S1.C2L.T.4GCS1 VS1 CS2 VS2 CS3 VS3 CS4 VS4 CS5 GST
MOMP GST-fusion Peptides (5 ug/ml)
FIG. 2. T-cell proliferation assay with C. trachomatis-specific
T-cell lines derived from serovar B MOMP-immunized BALB/c
mice. Nine GST fusion peptides spanning the MOMP were used as
antigens in this assay. GST was used as a control. Proliferation of
the T-cell line in response to each antigen was determined by the
addition of tritiated TdR on day 4 of culture. Incorporation was
measured after an 18-h incubation, and the results were reported as
the averages of triplicate wells. SI = counts per minute in antigen
wells/counts per minute in medium wells, where SI is the stimulation
index. These data are from one of three separate T-cell lines that
provided similar results.
primary spleen cells. However, in an in vivo functional assay
in which mice are immunized with each of the nine fusion
peptides and then challenged with intact organism, the VS3
peptide was significantly more effective in eliciting T-cell
help for the production of anti-EB antibodies than the other
eight MOMP peptides (1). Therefore, the results with T-cell
lines correspond more directly to the in vivo functional data
than analysis of primary spleen cell cultures.
Evaluation of VS3 sequence diversity. To evaluate the
potential role of sequence diversity in the T-cell response to
the GST-VS3 fusion peptide, T-cell lines were developed
from mice immunized with either serovar B MOMP or
serovar C MOMP and stimulated with the intact organism of
the homologous serovar. Proliferative responses of these
T-cell lines were then tested with VS3 fusion peptides with
amino acid sequences corresponding to either serovar B or
serovar C. Serovar B and serovar C were chosen for
evaluation, since they are the most sequence divergent and
antigenically distinct of the C. trachomatis serovariants. As
demonstrated in Fig. 3, whether the T cells were selected
with serovar B or serovar C antigen, both the VS3-B and the
VS3-C peptides stimulated T-cell proliferation. Thus, se-
quence diversity within the VS3 fragment did not signifi-
cantly influence T-cell recognition of this peptide in BALB/c
mice.
Mapping of T-cell recognition sites within VS3. The assay
format with short-term T-cell lines was used to map the
T-cell determinants within the large VS3 fusion peptide.
Fusion peptides that corresponded to the conserved amino-
terminal portion of GST-VS3 and the more variant sequence
carboxyl-terminal portion were designed (Fig. 1). The vari-
ant-sequence region of the VS3 fragment (peptides KE and
AE) was not capable of stimulating EB-selected T cells,
whereas the more conserved portion (GG) elicited T-cell
proliferation (Fig. 4). However, the smaller GG fragments
were not as effective a T-cell antigen as the full-size (GE)
GST-VS3 fragment. Optimal recognition may require the
larger GE fragment, since reactivity to this peptide may be
due to the presence of more than one T-cell determinant, or








BEB CEB VS3B VS3C GST BEB CEB VS3B VS3C GST
FIG. 3. T-cell proliferation assay with T-cell lines specific for
either serovar B or serovar C EBs. These cell lines were tested
against GST fusion peptides containing the VS3 sequence (GE) from
each serovar to assess the role of sequence diversity in the ability of
this MOMP segment to stimulate T-cell proliferation. (A) Serovar
B-specific T-cell line; (B) serovar C-specific T-cell line. These data
are from one of three separate T-cell lines for datum set A and one
of two cell lines for datum set B.
peptides. Analysis of the KE and GG fragments in an in vivo
functional assay was consistent with this result; only the
conserved GG fragment was capable of priming for a
MOMP-specific antibody response in BALB/c mice after
challenge with EBs (unpublished observation).
VS3-specific T-cell lines. We also evaluated whether T-cell
lines selected with the GST-VS3 fusion peptide could be
used for T-cell-determinant mapping as effectively as T cells
selected with EBs, since the fusion peptide would not be
processed in the same fashion as the native MOMP. T cells
A
Si Si
BEB GE-B GG-B KE-B GST CEB GE-C GG-C AE-C GST
FIG. 4. Mapping of T-cell recognition sites within VS3 with
T-cell lines stimulated with serovar B or serovar C EBs. GST fusion
proteins containing either all of VS3 (GE), the conserved portion of
VS3 (GG), or the variable portions of VS3 (KE and AE) were
evaluated for their ability to elicit T-cell proliferation. (A) T-cell line
stimulated with serovar B EBs and tested in assay with serovar B
EBs, GE (VS3B), GG (serovar B), and KE (serovar B); (B) T-cell
line stimulated with serovar C EBs and tested in assay with serovar
C EBs, GE (VS3C), GG (serovar C), and AE (serovar C). These
data are from one of two separate T-cell lines each for datum sets A
and B.
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BEB CEB GE-B GE-C GG-B KE-B GST
FIG. 5. Mapping of T-cell recognition sites within VS3 with a
VS3-B-specific T-cell line. Proliferation of a T-cell line selected by
using the GE fusion peptide was tested with serovar B and serovar
C EBs and the GE (serovar B), GE (serovar C), GG, and KE fusion
peptides. These data are from one of three separate T-cell lines that
provided similar results.
derived from MOMP-immunized mice were stimulated in
vitro with purified VS3 fusion peptide rather than intact
organism. These lines were tested against intact organism
and each of the VS3 fragments. The results are shown in Fig.
5. It was significant that T-cell lines selected by using the
VS3 fragment proliferated strongly in response to chlamyd-
iae, emphasizing the importance of this region as a T-cell
recognition sequence in the context of processing of the
entire bacterium. In addition, the observed pattern of reac-
tivity to GST-VS3 and the two fragments (KE and GG) was
identical to that seen with lines directed against the intact
organism. Thus, fine-mapping studies may be facilitated by
using cloned peptides to prepare T-cell lines.
DISCUSSION
The MOMP of C. trachomatis is the most promising
candidate antigen for designing a subunit vaccine for chla-
mydia infection. Protection is known to be serovariant
specific, and serovar-specific antibodies to MOMP neutral-
ize infectivity in vitro and in vivo (16). An understanding of
MOMP T-cell determinants is important, because protective
responses are T-cell dependent and a vaccine would require
T-cell priming of individuals to generate a rapid and specific
immune response following an encounter with the organism.
We used short-term T-cell lines to identify MOMP peptides
that are recognized by T cells. These were generated by
being primed in vivo with purified MOMP and selected in
vitro by stimulation with intact organisms. Organisms were
used for stimulation to ensure that T-cell determinants
recognized following immune processing of the entire organ-
ism could be identified.
With BALB/c T-cell lines, the peptide encompassing the
VS3 region, including the proximal conserved amino acids,
elicited the strongest proliferative response. Whether the T
cells were primed, stimulated, or tested with serovariant
homologous antigens or serovariant heterologous antigens,
T-cell proliferation to the VS3 peptide was observed. These
findings suggest that sequence variation within this peptide
does not affect recognition by the H-2d haplotype. This was
confirmed by using smaller peptides in which the peptide
containing the conserved amino acid sequence among sero-
variants was recognized and the peptide containing the
variable-sequence portion did not stimulate T-cell prolifera-
tion. T-cell proliferative responses to several MOMP pep-
tides have been observed when unselected immune spleen
cells are used (1, 15). Significantly, short-term chlamydia-
specific T-cell lines in this system restricted the response to
the region of MOMP containing VS3. The restricted re-
sponse of the T-cell lines to one peptide (i.e., VS3) compared
with the response in primary cultures to several peptides (1,
15) was a surprising finding, and this suggests that VS3
represents an immunodominant T-cell determinant (9). We
have previously found that this peptide, VS3, has the ability
to stimulate T cells in vivo that provide help to MOMP-
specific B cells (1). Thus, there is a striking correlation
between the in vitro proliferation of these lines and previ-
ously described in vivo analysis of T-cell help. This corre-
lation between functional assays and in vitro evaluation
provides a valuable tool for the analysis of T-cell determi-
nants for vaccine development.
Gajewski et al. (6) showed that different Th subsets
proliferate optimally to different antigen-presenting cell pop-
ulations and, in particular, that Th2 cells proliferate in
response to B cells, whereas Thl cells proliferate optimally
to radioresistant cell populations. The predominant antigen-
presenting cell in the primary spleen cell cultures is the
radioresistant dendritic cell or macrophage with some B-cell
contamination of the nylon wool-purified T cells. In the
short-term T-cell lines, high numbers of MOMP-specific
lymph node-derived B cells are present during the stimula-
tion culture. The presence of a large population of specific B
cells may select in vitro for the same population of T helper
cells that are effective in vivo for providing T-cell help for
the production of antibody. The ability of a particular
determinant to be processed and presented effectively by
MOMP-specific B cells may be the factor that results in the
relationship between the in vitro proliferative response of
short-term lines and the in vivo functional analysis. An
additional selection factor may occur, because EBs are used
during in vitro stimulation and constraints in the processing
of native organism-associated MOMP versus denatured
MOMP may limit the response to certain peptides.
The importance of VS3 as a T-helper determinant needs to
be evaluated by assessment of its function in multiple murine
haplotypes and evaluation of sequence diversity recognition
in each of these strains. Preliminary results with C3H mice
by the in vivo approach demonstrated that these mice
recognize the variant-sequence (KE) portion of VS3. How-
ever, these assays require large numbers of mice; therefore,
the number of variables that can be tested is limited.
Analysis of sequence variability in the C3H mouse response
and the fine specificity of T-cell determinants with other
strains of mice representing a variety of haplotypes should
be greatly facilitated by the use of T-cell lines rather than in
vivo assays. Thus, the short-term cell lines should facilitate
the analysis of multiple murine major histocompatibility
complex haplotypes and permit concurrent finer mapping of
the functionally important determinants in T-cell recogni-
tion. Preliminary data from one experiment with a T-cell line
derived from C3H mice showed strong proliferation to the
VS3 peptide. This suggests that recognition of T-cell deter-
minants within the VS3 peptide is not restricted only to the
H-2d haplotype. If the correlation between the proliferation
of short-term lines and functional T-cell help could be
demonstrated in humans by using peripheral blood lympho-
cytes, this would provide a valuable means to analyze the
human T-cell response to chlamydia antigens and allow a
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safe and relatively noninvasive means to evaluate large
numbers of individuals for their capacity to respond to
vaccine constructs prior to more-risky studies involving
immunization of human subjects.
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